A similar study showed another synthetic agonist of TLR9 that activated the phosphoinositide 3-kinase/protein kinase B signaling pathway and attenuated pathological cardiac hypertrophy and HF [91]. This evidence concerns the gene TLR9 and cardiac hypertrophy.